immunotherapy

2023 ASCO Annual Meeting; #ASCO23
May 25, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. Topics include treatment for anemia related to myelodysplastic syndromes, pembrolizumab for advanced cervical cancer, surgery options for early pancreatic cancer, weight loss in breast cancer survivorship, the effect of Medicare expansion on racial disparities, and collaborating across borders to help children with leukemia. Read More >>
ASCO ® Plenary Series
April 19, 2023 · Greg Guthrie, ASCO staff
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery. Read More >>
January 25, 2023 · Brielle Gregory Collins, ASCO staff
In this podcast, Dr. Christopher Flowers discusses new research from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, including new treatments for non-Hodgkin lymphoma and models for predicting early disease progression. Read More >>
ASCO ® Plenary Series
December 19, 2022 · Greg Guthrie, ASCO staff
Read research from the December 2022 session of the ASCO Plenary Series, which explores combining immunotherapy for advanced non-small cell lung cancer with high PD-L1. Read More >>
December 12, 2022 · Greg Guthrie, ASCO staff
A study from China published in the Journal of Clinical Oncology has shown that CAR T-cell therapy that targets CD19 and CD22 is effective at treating recurrent or refractory acute lymphoblastic leukemia in children. Read More >>

Pages